References
- American Cancer Society. Cancer Facts and Figures. Atlanta, GA, USA (2006).
- Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J. Clin.53, 5–26 (2003).
- Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N. Engl. J. Med.351, 998–1012 (2004).
- Dennis LK, Beane Freeman LE, VanBeek MJ. Sunscreen use and the risk for melanoma: a quantitative review. Ann. Intern. Med.139, 966–978 (2003).
- Demierre MF, Nathanson L. Chemoprevention of melanoma: an unexplored strategy. J. Clin. Oncol.21, 158–165 (2003).
- Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene22, 3138–3151 (2003).
- Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol.19, 3635–3648 (2001).
- Gilchrest BA, Eller MS, Geller AC et al. The pathogenesis of melanoma induced by ultraviolet radiation. N. Engl. J. Med.340, 1341–1348 (1999).
- The Molecular Basis of Cancer. Mendelsohn J, Howley P, Israel M et al. (Eds). WB Saunders Company, PA, USA (2001).
- Meyskens FL Jr, Farmer PJ, Anton-Culver H. Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk. Clin. Cancer Res.10, 2581–2583 (2004).
- Albino AP, Nanus DM, Mentle IR et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene4, 1363–1374 (1989).
- Pollock PM, Yu F, Qiu L et al. Evidence for U.V. induction of CDKN2 mutations in melanoma cell lines. Oncogene11, 663–668 (1995).
- Papp T, Pemsel H, Rollwitz I et al. Mutational analysis of N-ras, p53, CDKN2A (p16(INK4a)), p14(ARF), CDK4, and MC1R genes in human dysplastic melanocytic naevi. J. Med. Genet.40, E14 (2003).
- Smalley KS, Brafford PA, Herlyn M. Selective evolutionary pressure from the tissue microenvironment drives tumor progression. Semin. Cancer Biol.15, 451–459 (2005).
- Vink AA, Moodycliffe AM, Shreedhar V et al. The inhibition of antigen-presenting activity of dendritic cells resulting from UV irradiation of murine skin is restored by in vitro photorepair of cyclobutane pyrimidine dimers. Proc. Natl Acad. Sci. USA94, 5255–5260 (1997).
- Halaban R. Growth factors and melanomas. Semin. Oncol.23, 673–681 (1996).
- Bernards R, Weinberg RA. A progression puzzle. Nature418, 823 (2002).
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell100, 57–70 (2000).
- Torrance CJ, Jackson PE, Montgomery E et al. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med.6, 1024–1028 (2000).
- Hawk E, Viner JL. The critical role of risk–benefit assessments in cancer prevention. Cancer Epidemiol. Biomarkers Prev.14, 297–298 (2005).
- Wilhelm SM, Carter C, Tang L et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64, 7099–7109 (2004).
- Lee JJ, Hong WK, Hittelman WN et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin. Cancer Res.6, 1702–1710 (2000).
- Demierre MF, Sondak VK. Chemoprevention of melanoma: theoretical and practical considerations. Cancer Control12, 219–222 (2005).
- Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature417, 949–954 (2002).
- Uribe P, Andrade L, Gonzalez S. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J. Invest. Dermatol.126, 161–166 (2006).
- Demierre MF, Higgins PD, Gruber SB et al. Statins and cancer prevention. Nat. Rev. Cancer5, 930–942 (2005).
- Demierre MF, Sondak VK. Cutaneous melanoma: pathogenesis and rationale for chemoprevention. Crit. Rev. Oncol. Hematol.53, 225–239 (2005).
- Collisson EA, Kleer C, Wu M et al. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol. Cancer Ther.2, 941–948 (2003).
- Dellavalle RP, Drake A, Graber M et al. Statins and fibrates for preventing melanoma. Cochrane Database Syst. Rev. CD003697 (2005).
- Poynter JN, Gruber SB, Higgins PD et al. Statins and the risk of colorectal cancer. N. Engl. J. Med.352, 2184–2192 (2005).
- Mukhopadhyay A, Basu N, Ghatak N et al. Anti-inflammatory and irritant activities of curcumin analogues in rats. Agents Actions12, 508–515 (1982).
- Srimal RC, Dhawan BN. Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J. Pharm. Pharmacol.25, 447–452 (1973).
- Rao CV, Rivenson A, Simi B et al. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res.55, 259–266 (1995).
- Huang MT, Smart RC, Wong CQ et al. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res.48, 5941–5946 (1988).
- Huang MT, Lou YR, Ma W et al. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res.54, 5841–5847 (1994).
- Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res.23, 363–398 (2003).
- Lu YP, Chang RL, Lou YR et al. Effect of curcumin on 12-O-tetradecanoylphorbol-13-acetate- and ultraviolet B light-induced expression of c-Jun and c-Fos in JB6 cells and in mouse epidermis. Carcinogenesis15, 2363–2370 (1994).
- Azuine MA, Bhide SV. Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical carcinogens in Swiss mice. Nutr. Cancer17, 77–83 (1992).
- Huang MT, Newmark HL, Frenkel K. Inhibitory effects of curcumin on tumorigenesis in mice. J. Cell. Biochem. Suppl.27, 26–34 (1997).
- Limtrakul P, Lipigorngoson S, Namwong O et al. Inhibitory effect of dietary curcumin on skin carcinogenesis in mice. Cancer Lett.116, 197–203 (1997).
- Ishizaki C, Oguro T, Yoshida T et al. Enhancing effect of ultraviolet A on ornithine decarboxylase induction and dermatitis evoked by 12-O-tetradecanoylphorbol-13-acetate and its inhibition by curcumin in mouse skin. Dermatology193, 311–317 (1996).
- Subramanian M, Sreejayan, Rao MN et al. Diminution of singlet oxygen-induced DNA damage by curcumin and related antioxidants. Mutat. Res.311, 249–255 (1994).
- Lin JK, Shih CA. Inhibitory effect of curcumin on xanthine dehydrogenase/oxidase induced by phorbol-12-myristate-13-acetate in NIH3T3 cells. Carcinogenesis15, 1717–1721 (1994).
- Rao CV, Simi B, Redd S. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis14, 2219–2225 (1993).
- Flynn DL, Rafferty MF, Boctor AM. Inhibition of 5-hydroxy-eicosatetraenoic acid (5-HETE) formation in intact human neutrophils by naturally-occurring diarylheptanoids: inhibitory activities of curcuminoids and yakuchinones. Prostaglandins Leuk. Med.22, 357–360 (1986).
- Han SS, Chung ST, Robertson DA et al. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-κB, and p53. Clin. Immunol.93, 152–161 (1999).
- Mukhopadhyay A, Bueso-Ramos C, Chatterjee D et al. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene20, 7597–7609 (2001).
- Bush JA, Cheung KJ Jr, Li G. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp. Cell. Res.271, 305–314 (2001).
- Grandjean-Laquerriere A, Gangloff SC, Le Naour R et al. Relative contribution of NF-κB and AP-1 in the modulation by curcumin and pyrrolidine dithiocarbamate of the UVB-induced cytokine expression by keratinocytes. Cytokine18, 168–177 (2002).
- Huang MT, Lysz T, Ferraro T et al. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res.51, 813–819 (1991).
- Menon LG, Kuttan R, Kuttan G. Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett.95, 221–225 (1995).
- Cheng AL, Hsu CH, Lin JK et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res.21, 2895–2900 (2001).
- Sharma RA, McLelland HR, Hill KA et al. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin. Cancer Res.7, 1894–1900 (2001).
- Shoba G, Joy D, Joseph T et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med.64, 353–356 (1998).
- Aziz MH, Kumar R, Ahmad N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int. J. Oncol.23, 17–28 (2003).
- Bhat KP, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Ann. NY Acad. Sci.957, 210–229 (2002).
- Aggarwal BB, Bhardwaj A, Aggarwal RS et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res.24, 2783–2840 (2004).
- Afaq F, Adhami VM, Ahmad N. Prevention of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice. Toxicol. Appl. Pharmacol.186, 28–37 (2003).
- Ciolino HP, Daschner PJ, Yeh GC. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res.58, 5707–5712 (1998).
- Burkitt MJ, Duncan J. Effects of trans-resveratrol on copper-dependent hydroxyl-radical formation and DNA damage: evidence for hydroxyl-radical scavenging and a novel, glutathione-sparing mechanism of action. Arch. Biochem. Biophys.381, 253–263 (2000).
- Adhami VM, Afaq F, Ahmad N. Involvement of the retinoblastoma (pRb)-E2F/DP pathway during antiproliferative effects of resveratrol in human epidermoid carcinoma (A431) cells. Biochem. Biophys. Res. Commun.288, 579–585 (2001).
- Holmes-McNary M, Baldwin AS Jr. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IκB kinase. Cancer Res.60, 3477–3483 (2000).
- Yang S, Meyskens FL Jr. Alterations in activating protein 1 composition correlate with phenotypic differentiation changes induced by resveratrol in human melanoma. Mol. Pharmacol.67, 298–308 (2005).
- Ragione FD, Cucciolla V, Criniti V et al. p21Cip1 gene expression is modulated by Egr1: a novel regulatory mechanism involved in the resveratrol antiproliferative effect. J. Biol. Chem.278, 23360–23368 (2003).
- Niles RM, McFarland M, Weimer MB et al. Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett.190, 157–163 (2003).
- Fulda S, Debatin KM. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res.64, 337–346 (2004).
- Bertelli A, Bertelli AA, Gozzini A et al. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp. Clin. Res.24, 133–138 (1998).
- Larrosa M, Tomas-Barberan FA, Espin JC. The grape and wine polyphenol piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells. Eur. J. Nutr.43, 275–284 (2004).
- De Santi C, Pietrabissa A, Spisni R et al. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica30, 857–866 (2000).
- Juan ME, Vinardell MP, Planas JM. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J. Nutr.132, 257–260 (2002).
- Singh RP, Agarwal R. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur. J. Cancer41, 1969–1979 (2005).
- Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs61, 2035–2063 (2001).
- Katiyar SK, Korman NJ, Mukhtar H et al. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J. Natl Cancer Inst.89, 556–566 (1997).
- Baeuerle PA, Baichwal VR. NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv. Immunol.65, 111–137 (1997).
- Manna SK, Mukhopadhyay A, Van NT et al. Silymarin suppresses TNF-induced activation of NF-κB, c-Jun N-terminal kinase, and apoptosis. J. Immunol.163, 6800–6809 (1999).
- Saliou C, Kitazawa M, McLaughlin L et al. Antioxidants modulate acute solar ultraviolet radiation-induced NF-κ-B activation in a human keratinocyte cell line. Free Radic. Biol. Med.26, 174–183 (1999).
- Mohan S, Dhanalakshmi S, Mallikarjuna GU et al. Silibinin modulates UVB-induced apoptosis via mitochondrial proteins, caspases activation, and mitogen-activated protein kinase signaling in human epidermoid carcinoma A431 cells. Biochem. Biophys. Res. Commun.320, 183–189 (2004).
- Chen PN, Hsieh YS, Chiou HL et al. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem. Biol. Interact.156, 141–150 (2005).
- Tanamly MD, Tadros F, Labeeb S et al. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig. Liver Dis.36, 752–759 (2004).
- Katiyar SK, Elmets CA. Green tea polyphenolic antioxidants and skin photoprotection (Review). Int. J. Oncol.18, 1307–1313 (2001).
- Vayalil PK, Elmets CA, Katiyar SK. Treatment of green tea polyphenols in hydrophilic cream prevents UVB-induced oxidation of lipids and proteins, depletion of antioxidant enzymes and phosphorylation of MAPK proteins in SKH-1 hairless mouse skin. Carcinogenesis24, 927–936 (2003).
- Agarwal R, Katiyar SK, Khan SG et al. Protection against ultraviolet B radiation-induced effects in the skin of SKH-1 hairless mice by a polyphenolic fraction isolated from green tea. Photochem. Photobiol.58, 695–700 (1993).
- Katiyar SK, Matsui MS, Elmets CA et al. Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea reduces UVB-induced inflammatory responses and infiltration of leukocytes in human skin. Photochem. Photobiol.69, 148–153 (1999).
- Katiyar SK, Perez A, Mukhtar H. Green tea polyphenol treatment to human skin prevents formation of ultraviolet light B-induced pyrimidine dimers in DNA. Clin. Cancer Res.6, 3864–3869 (2000).
- Mittal A, Piyathilake C, Hara Y et al. Exceptionally high protection of photocarcinogenesis by topical application of (--)-epigallocatechin-3-gallate in hydrophilic cream in SKH-1 hairless mouse model: relationship to inhibition of UVB-induced global DNA hypomethylation. Neoplasia5, 555–565 (2003).
- Kim J, Hwang JS, Cho YK et al. Protective effects of (-)-epigallocatechin-3-gallate on UVA- and UVB-induced skin damage. Skin Pharmacol. Appl. Skin Physiol.14, 11–19 (2001).
- Katiyar SK, Challa A, McCormick TS et al. Prevention of UVB-induced immunosuppression in mice by the green tea polyphenol (-)-epigallocatechin-3-gallate may be associated with alterations in IL-10 and IL-12 production. Carcinogenesis20, 2117–2124 (1999).
- Nihal M, Ahmad N, Mukhtar H et al. Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int. J. Cancer114, 513–521 (2005).
- Liu JD, Chen SH, Lin CL et al. Inhibition of melanoma growth and metastasis by combination with (-)-epigallocatechin-3-gallate and dacarbazine in mice. J. Cell. Biochem.83, 631–642 (2001).
- Ley RD. Ultraviolet radiation A-induced precursors of cutaneous melanoma in Monodelphis domestica. Cancer Res.57, 3682–3684 (1997).
- Walter RB, Kazianis S. Xiphophorus interspecies hybrids as genetic models of induced neoplasia. ILAR J.42, 299–321 (2001).
- Bradl M, Klein-Szanto A, Porter S et al. Malignant melanoma in transgenic mice. Proc. Natl Acad. Sci. USA88, 164–168 (1991).
- Noonan FP, Dudek J, Merlino G et al. Animal models of melanoma: an HGF/SF transgenic mouse model may facilitate experimental access to UV initiating events. Pigment Cell Res.16, 16–25 (2003).